Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has received an average rating of "Hold" from the twenty-seven analysts that are covering the company, Marketbeat Ratings reports. Nineteen equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $73.35.
Several equities analysts have issued reports on the company. Wells Fargo & Company lowered Intercept Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $146.00 to $46.00 in a research note on Monday, June 29th. BMO Capital Markets cut Intercept Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $107.00 to $52.00 in a research report on Monday, June 29th. Oppenheimer reaffirmed a "hold" rating and set a $54.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 11th. Stifel Nicolaus upped their price target on Intercept Pharmaceuticals from $51.00 to $56.00 and gave the company a "hold" rating in a research report on Monday, August 10th. Finally, SVB Leerink dropped their price target on Intercept Pharmaceuticals from $89.00 to $50.00 and set a "market perform" rating on the stock in a research report on Tuesday, June 30th.
ICPT stock opened at $43.41 on Wednesday. The company has a debt-to-equity ratio of 10.32, a quick ratio of 3.71 and a current ratio of 3.71. The stock has a market cap of $1.43 billion, a P/E ratio of -4.19 and a beta of 1.62. The firm has a 50 day simple moving average of $47.34 and a 200 day simple moving average of $65.06. Intercept Pharmaceuticals has a 52 week low of $40.30 and a 52 week high of $125.00.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($2.94) by $1.02. Intercept Pharmaceuticals had a negative return on equity of 1,973.10% and a negative net margin of 119.73%. The firm had revenue of $77.60 million for the quarter, compared to analysts' expectations of $72.45 million. During the same quarter in the previous year, the business posted ($2.28) earnings per share. The business's revenue for the quarter was up 17.0% on a year-over-year basis. Sell-side analysts predict that Intercept Pharmaceuticals will post -8.2 EPS for the current year.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 54,600 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $50.55, for a total value of $2,760,030.00. Following the completion of the sale, the director now owns 21,028 shares in the company, valued at approximately $1,062,965.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder S.P.A. Genextra sold 1,362,400 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $47.07, for a total value of $64,128,168.00. Following the completion of the sale, the insider now owns 5,417,000 shares of the company's stock, valued at approximately $254,978,190. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,501,192 shares of company stock valued at $71,310,546. Company insiders own 23.70% of the company's stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System purchased a new position in shares of Intercept Pharmaceuticals in the first quarter valued at about $387,000. New York State Common Retirement Fund lifted its position in shares of Intercept Pharmaceuticals by 3.8% in the first quarter. New York State Common Retirement Fund now owns 29,336 shares of the biopharmaceutical company's stock worth $1,847,000 after buying an additional 1,079 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Intercept Pharmaceuticals by 1.7% in the first quarter. Rhumbline Advisers now owns 36,442 shares of the biopharmaceutical company's stock worth $2,294,000 after buying an additional 594 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Intercept Pharmaceuticals by 17.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,080 shares of the biopharmaceutical company's stock worth $131,000 after buying an additional 312 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Intercept Pharmaceuticals by 1.4% in the first quarter. Swiss National Bank now owns 50,800 shares of the biopharmaceutical company's stock worth $3,198,000 after buying an additional 700 shares in the last quarter. Institutional investors and hedge funds own 80.78% of the company's stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: Relative Strength Index
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 "Past Their Prime" Stocks to Dump From Your Portfolio
Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.
As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.
We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.
View the "20 "Past Their Prime" Stocks to Dump From Your Portfolio".